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Text: Background and objective: Spinal cord atrophy occurs in multiple sclerosis (MS) and has been
proposed as a measure of neurodegeneration. The aim of this longitudinal study is to quantify spinal
cord atrophy to evaluate its association with clinical disability and other MRI measures.
Materials and methods: 31 patients (12 women; median age, 51 years; age range, [33, 61],
baseline EDSS median, 5.5; baseline EDSS range, [3, 6.5]) diagnosed of primary progressive MS,
underwent three serial 1.5 T brain and spinal cord MRI examinations (baseline, year 2, and year 7),
including the following sequences: PD/T2, 2D T1-weighted, and a spinal cord 3D magnetization
prepared rapid acquisition gradient echo (MPRAGE) T1-weighted. Spinal cord from C1 to C5 was
segmented in MRI scan using the spinal cord tool included in Jim 6.0. Using this method we
evaluated global cross-sectional spinal cord area (CSA), and CSA at C2-C3 (C23), C3-C4 (C34),
and C4-C5 (C45) levels. CSA measurements were then normalized (CSAn, C23n, C34n, C45n) to
the intra-cranial cross-sectional area measured at the inferior margins of the corpus callosum on an
axial slice of the proton density-weighted image of each subject. Percentage of change in spinal
cord measurements between baseline and 7th year exam were averaged per year of evolution. T2
lesion load (T2LL), T1 lesion load (T1LL), and brain parenchymal fraction (BPF) were measured at
each time point. EDSS was also evaluated as the area under the curve of EDSS values in each time
point normalized by the maximum area (AUCNEDSS). Partial correlations controlled for age and sex
were performed to evaluate the relationship between spinal cord measurements and radiological or
clinical measurements.
Results: All normalized CSA measurements showed moderate correlations with AUCNEDSS
ranging between -0.4872 and -0.3717 (p< 0.05). In addition, the mean annual percentage of change
in normalized CSA (pyCSAn: -0.7715%; pyC23n: -0.6155%; pyC34n: -0.7376%; pyC45n:
-0.7720%) showed significant correlations with baseline BPF (pyC23n vs. BPF: r=-0.4514, p=0.014;
pyC34n vs. BPF: r=-0.4556, p=0.013). Mean annual percentage of change in C34n also correlated
with BPF at year 2 (r=-0.3688, p=0.049).
Conclusions: Results suggest that development of spinal cord atrophy is associated with increasing
disability. Moreover, patients presenting larger baseline BPF seem to show a greater tendency for
future spinal cord atrophy development at some cervical levels.
Disclosure: F. Xavier Aymerich has nothing to disclose.
Manel Alberich has nothing to disclose.
Cristina Auger has received speaking honoraria from Novartis and Genzyme.
Jaume Sastre-Garriga has received compensation for consulting services and speaking honoraria
from Merck-Serono, Biogen-Idec, Teva, Sanofi-Aventis and Novartis.
Xavier Montalban has received speaking honoraria and travel expenses for scientific meetings, has
been a steering committee member of clinical trials or participated in advisory boards of clinical
trials in the past with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech,
Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals and Almirall.
Alex Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA
Medical, and has received speaker honoraria from Bayer, Genzyme, Sanofi-Aventis, Bracco,
Merck-Serono, Teva Pharmaceutical Industries Ltd, OLEA Medical, Stendhal, Novartis and Biogen
Idec.
Picture: 1426-PIC-1432028120.jpg
Travel Grant /
Young Scientific Investigator's
Sessions:
I will not apply for Travel Grant or Young Scientific Investigator's Sessions
 
 
Conference: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis · Abstract: A-733-0022-01426 ·
Status: Draft  
  
31st Congress of the European Committee for Treatment and Research i... http://www.abstractserver.com/ectrims2015/absmgm/printpreview.php?
1 de 1 19/05/2015 16:42
